Login

Financial Snapshot

Revenue
TTM
$3.046B
Gross Margin
TTM
38.81%
Net Income
TTM
$122.1M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
246.95%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
$3.500B
Book Value
2026 Q1
$39.94M
Cash
2026 Q1
P/E
TTM
33.05
Free Cash Flow
TTM
$201.6M

Stock Price

Loading...
Market Cap: $4.0356 Billion

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Industry: Pharmaceutical Preparations Peers: Innoviva Inc AERIE PHARMACEUTICALS INC BIODELIVERY SCIENCES INTERNATIONAL INC DICE Therapeutics, Inc. Nektar Therapeutics Johnson & Johnson REATA PHARMACEUTICALS INC SIGA Technologies Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support